Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

咱们都知道，MASH长期以来缺乏有效的治疗手段，患者往往依赖于生活方式干预或面临肝移植的风险。现在，随着Rezdiffra的成功上市以及GSK等公司的积极布局，MASH治疗领域正逐渐从“研发黑洞”转变为充满希望的商业化蓝海。未来，靶点的选择优化、非侵入性诊断方法的应用以及联合疗法的研究将成为该领域发展的关键。

Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their ...

In another note of news, a key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's ( NVO) Wegovy (semaglutide) and Eli Lilly's ( LLY) Zepbound ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

说起在MASH赛道屡战屡败又屡败屡战，一定少不了吉利德。去年10月，吉利德宣布已终止与韩国生物技术公司Yuhan就两种MASH疗法的合作和许可协议。这场合作始于2019年1月，吉利德科学和韩国Yuhan公司两家公司已经签订了一项许可和合作协议，将共同 ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

Efimosfermin Alfa一项随机、双盲、安慰剂对照的二期临床：在84名经活检确诊的F2或F3纤维化MASH患者中（治疗组接受每月一次300mg的Efimosfermin ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...